Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My NCBI Filters

Results by year

Table representation of search results timeline featuring number of search results per year.

Year Number of Results
2006 2
2007 3
2008 5
2009 2
2010 1
2012 2
2013 1
2014 2
2015 1
2017 1
2018 1
2021 1
2022 1
2024 1

Text availability

Article attribute

Article type

Publication date

Search Results

22 results

Results by year

Filters applied: . Clear all
Page 1
Sunlight exposure exerts immunomodulatory effects to reduce multiple sclerosis severity.
Ostkamp P, Salmen A, Pignolet B, Görlich D, Andlauer TFM, Schulte-Mecklenbeck A, Gonzalez-Escamilla G, Bucciarelli F, Gennero I, Breuer J, Antony G, Schneider-Hohendorf T, Mykicki N, Bayas A, Then Bergh F, Bittner S, Hartung HP, Friese MA, Linker RA, Luessi F, Lehmann-Horn K, Mühlau M, Paul F, Stangel M, Tackenberg B, Tumani H, Warnke C, Weber F, Wildemann B, Zettl UK, Ziemann U, Müller-Myhsok B, Kümpfel T, Klotz L, Meuth SG, Zipp F, Hemmer B, Hohlfeld R, Brassat D, Gold R, Gross CC, Lukas C, Groppa S, Loser K, Wiendl H, Schwab N; German Competence Network Multiple Sclerosis (KKNMS) and the BIONAT Network. Ostkamp P, et al. Proc Natl Acad Sci U S A. 2021 Jan 5;118(1):e2018457118. doi: 10.1073/pnas.2018457118. Proc Natl Acad Sci U S A. 2021. PMID: 33376202 Free PMC article.
Communication, Coordination, and Security for People with Multiple Sclerosis (COCOS-MS): a randomised phase II clinical trial protocol.
Golla H, Dillen K, Hellmich M, Dojan T, Ungeheuer S, Schmalz P, Staß A, Mildenberger V, Goereci Y, Dunkl V, Strupp J, Fink GR, Voltz R, Stock S, Cornely O, Stahmann A, Müller A, Löcherbach P, Burghaus L, Limmroth V, Bonmann E, Gerbershagen K, Nelles G, Joist T, Haas J, Temmes H, Warnke C. Golla H, et al. Among authors: gerbershagen k. BMJ Open. 2022 Jan 25;12(1):e049300. doi: 10.1136/bmjopen-2021-049300. BMJ Open. 2022. PMID: 35078833 Free PMC article.
Anti-JC-virus antibody prevalence in a German MS cohort.
Warnke C, Dehmel T, Posevitz-Fejfár A, Chan A, Berthele A, Schmidt S, Haas J, Kronsbein HC, Seitz F, Tackenberg B, Mäurer M, Gerbershagen K, Limmroth V, Adams O, Hartung HP, Gold R, Hemmer B, Wiendl H, Kieseier BC. Warnke C, et al. Among authors: gerbershagen k. Mult Scler. 2012 Jul;18(7):1054-5. doi: 10.1177/1352458511429955. Mult Scler. 2012. PMID: 22740609 No abstract available.
Electrocardiographic assessments and cardiac events after fingolimod first dose - a comprehensive monitoring study.
Limmroth V, Ziemssen T, Lang M, Richter S, Wagner B, Haas J, Schmidt S, Gerbershagen K, Lassek C, Klotz L, Hoffmann O, Albert C, Schuh K, Baier-Ebert M, Wendt G, Schieb H, Hoyer S, Dechend R, Haverkamp W. Limmroth V, et al. Among authors: gerbershagen k. BMC Neurol. 2017 Jan 18;17(1):11. doi: 10.1186/s12883-016-0789-7. BMC Neurol. 2017. PMID: 28100182 Free PMC article.
[Clinical implications of meningococcal disease].
Kuhn J, Gerbershagen K, Mennel HD, Bewermeyer H. Kuhn J, et al. Among authors: gerbershagen k. Dtsch Med Wochenschr. 2006 Feb 3;131(5):209-13. doi: 10.1055/s-2006-924950. Dtsch Med Wochenschr. 2006. PMID: 16440268 German. No abstract available.
Alemtuzumab as rescue therapy in a cohort of 50 relapsing-remitting MS patients with breakthrough disease on fingolimod: a multi-center observational study.
Huhn K, Bayas A, Doerck S, Frank B, Gerbershagen K, Hellwig K, Kallmann B, Kleinschnitz C, Kleiter I, Lee DH, Limmroth V, Mäurer M, Meuth S, Rieckmann P, Ruck T, Gold R, Linker RA. Huhn K, et al. Among authors: gerbershagen k. J Neurol. 2018 Jul;265(7):1521-1527. doi: 10.1007/s00415-018-8871-2. Epub 2018 Apr 25. J Neurol. 2018. PMID: 29696498
"So at least now I know how to deal with things myself, what I can do if it gets really bad again"-experiences with a long-term cross-sectoral advocacy care and case management for severe multiple sclerosis: a qualitative study.
Müller A, Hebben F, Dillen K, Dunkl V, Goereci Y, Voltz R, Löcherbach P, Warnke C, Golla H; COCOS-MS trial group represented by Martin Hellmich. Müller A, et al. BMC Health Serv Res. 2024 Apr 10;24(1):453. doi: 10.1186/s12913-024-10851-1. BMC Health Serv Res. 2024. PMID: 38600493 Free PMC article.
22 results